Ignite Creation Date:
2024-05-05 @ 7:17 PM
Last Modification Date:
2024-10-26 @ 9:46 AM
Study NCT ID:
NCT00640848
Status:
COMPLETED
Last Update Posted:
2016-02-12
First Post:
2008-03-18
Brief Title:
Almorexant in Primary Insomnia
Sponsor:
Midnight Pharma LLC
Organization:
Midnight Pharma LLC
Study Overview
Official Title:
Multi-center Multiple-stage Double-blind Randomized Placebo-controlled Two-way Crossover Single-dose Study to Investigate the Effects of ACT-078573 on Sleep Measured by Polysomnography in Patients With Primary Insomnia
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Insomnia
Brief Summary:
The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep efficiency and to assess the effects of different doses of ACT-078573 on other PSG parameters
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None